A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

Akito Takamura,Shintaro Hirata,Hayato Nagasawa,Hideto Kameda,Yohei Seto,Tatsuya Atsumi,Makoto Dohi,Takao Koike,Nobuyuki Miyasaka,Masayoshi Harigai

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

2013

Akito Takamura
Shintaro Hirata
Hayato Nagasawa
Hideto Kameda
Yohei Seto
Tatsuya Atsumi
Makoto Dohi
Takao Koike
Nobuyuki Miyasaka
Masayoshi Harigai

Objective We investigated associations between treatment with methotrexate (MTX) or biological disease-modifying antirheumatic drugs (DMARDs) and elevation of serum Krebs von den Lungen-6 (KL-6) levels in Japanese patients with rheumatoid arthritis (RA).

Keywords:

Antirheumatic drugs
Physical therapy
Rheumatology
Rheumatoid arthritis
Retrospective cohort study
Disease
Diabetes mellitus
Methotrexate
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations